Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03498170 · ClinicalTrials.gov registry record · Phase 1

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

A Phase 1 study of Interaction, sponsored by Mereo BioPharma.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT03498170: Completed Phase 1 study of Interaction, sponsored by Mereo BioPharma.

NCT03498170 is a Phase 1 study of Interaction that has completed, run by Mereo BioPharma. The registered enrollment target is 16 participants, below the 23-participant average among 3 other Interaction trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03498170, a Phase 1 study of Interaction, has completed, sponsored by Mereo BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants.

Primary Outcome

Period 1: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144 and 168 hours post BCT197 dose on Day 1. Period 2: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144, 168 and 192 hours post BCT197 dose on Day 7.

Conditions Studied

Interventions

  • DRUG Itraconazole 200 mg
  • DRUG BCT197

Study Locations (1)

Florida

  • inVentiv Health Clinical Research Services LLC - Miami

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-03-19
Est. Completion 2018-05-09
Phase Phase 1
Mereo BioPharma

10 total trials

What the finished NCT03498170 record still lists

NCT03498170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 23-participant average among 3 other Interaction trials with a reported enrollment target (30% lower).

The record links to 1 condition, with Interaction appearing as the primary indexed condition, and to 2 interventions - of which Itraconazole 200 mg is the first listed.

NCT03498170 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03498170 about?

NCT03498170 is a clinical study titled "The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants". An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants.

What is the current status of trial NCT03498170?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-19. Estimated completion is 2018-05-09.

What conditions does trial NCT03498170 study?

This clinical trial studies the following conditions: Interaction.

What interventions are being tested in trial NCT03498170?

The interventions under investigation include: Itraconazole 200 mg (DRUG), BCT197 (DRUG).

Who is sponsoring clinical trial NCT03498170?

This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03498170 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Interaction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03498170, the US trial registry maintained by the National Library of Medicine. NCT03498170 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.